At a glance
- Originator Aventis
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic complications
Most Recent Events
- 09 May 2003 Discontinued - Preclinical for Diabetic complications in USA (unspecified route)
- 17 Apr 1997 No-Development-Reported for Diabetic complications in USA (Unknown route)
- 15 Dec 1994 Preclinical development for Diabetic complications in USA (Unknown route)